Company news

Xvivo Perfusion AB news in 2026

Xvivo Perfusion AB's news releases, calls and decks from 2026, newest first.

View company

XVIVO announces FDA receipt of PMA application for the XVIVO Heart Assist Transport System

September 28, 2026

XVIVO receives CE certificates for its groundbreaking heart preservation technology, transforming access to life-saving transplants across Europe

August 11, 2026

XVIVO granted additional patient enrollment in the US PRESERVE CAP study for XVIVO Heart Assist Transport

August 3, 2026

Interim Report January - June 2026

July 14, 2026

Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology

May 18, 2026

Regulatory derogation and reimbursement in France enable life-saving use of XVIVO’s heart technology

May 18, 2026

Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation

April 22, 2026

The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal

April 16, 2026

Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)

March 19, 2026

CORRECTION FROM SOURCE: The Nomination Committee's Proposal for New Board Members

February 20, 2026

The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors

February 20, 2026

Management Change at XVIVO - CFO Transitions to New Role

February 19, 2026

Change of Date for Publication of the Interim Report January-March 2026

February 10, 2026

XVIVO's CEO to present at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco

January 6, 2026

Calls in 2026

Decks in 2026